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Introduction 
Recognition by CD4+ T cells of pathogen-derived antigenic peptides bound 
to class II MHC molecules (MHCII) and expressed on the surface of 
antigen presenting cells (APCs) is a crucial step in the initiation of an 
adaptive immune response. The ability to predict whether a peptide 
sequence binds to an MHCII can aid the development of vaccines, as well 
as provide the biochemical and biophysical underpinning to the 
measurement of immune response.  
Current informatics systems employed to predict MHCII/peptide 
presentation were developed on the basis of a rigid docking model and in 
conditions emulating the extracellular environment at pH 7.4. These 
methods suffer from low accuracy, most likely because they ignore the 
flexibility of the peptide/MHCII system, as well as the varying levels of 
acid pH the complex experiences within the endosome, where the peptide 
binding reaction usually occurs. Therefore, using the human allele HLA-
DR1 (DR1), and a library of peptides derived via cycle mutation (Table I)  
from the sequence of HA peptide (H3 strain) residues 306-319, we have 
evaluated the impact of solvent protonation on peptide/DR1 (pDR1) 
complex flexibility, measured as cooperativity, with the long-term goal of 




Cooperativity in a multipoint ligand-receptor binding event is evidenced by a 
disproportion between the observed affinity value and the expected value based on 
multiplication of affinity values of single residue exchange. A general strategy to 
investigate the occurrence of such a phenomenon is the mutant cycle approach. This 
consists in introducing multiple substitutions in the sequence of peptides and 
assessing their binding abilities. If the effect on the binding affinity of the double (or 
triple) mutation is not equal to the product of effects of the single mutations, then the 
two (or three) residues are coupled (cooperative). We are applying this strategy to 
determine the extent of cooperativity the pDR1system undergoes during formation. 
We began our analysis of cooperativity in peptide binding to DR1 by measuring the 
affinity of the wtHA peptide and the peptides with single substitutions at pH 5.4, pH 
6.4, and pH 7.4, then transitioning to peptides with multiple substitutions.  Results of 
these initial experiments reveal that  multiple substitutions in the peptide sequence 
greatly affect the binding affinity of the peptide to DR1, most notably in acidic 
conditions, where binding affinity can be altered by an order of magnitude (Table II). 
 
Materials and Methods 
 
Peptides were derived from the sequence GPKYVKQNTLKLAT, representing residues 
306-319 of the hemagglutinin protein from influenza A virus (H3 subtype). The N-
terminal Gly facilitated labeling. N-terminal labeling with or LC-LC biotin (Pierce) was 
performed (Anaspec, CA).  
 
Recombinant soluble empty (peptide free) DR1 was produced and purified by ion-
exchange chromatography from a stably transfected CHO cell line. DR1 proteins were 
quantified by measuring the UV absorbance @ 280 nm using an E280 of 56340 M-1 cm-1 
before use(Amicon, Pierce). 
 
DR1 (20 nm) was incubated with 20 nm biotinylated HA peptide in PBST (pH7.4), MES 
(pH6.4), and Sodium Citrate (pH5.4) in the presence of varying amounts of inhibitor 
peptides at 37˚C. Bound biotinylated peptide was detected using a solid-phase 
immunoassay and Eu2+ labeled streptavidin. Plates were read using a Perkin Elmer 
Victor X5. IC50 values were obtained from the curve fit of the binding data and 
converted to KD values by using the Cheng-Prusoff equation KD = (IC50)/(1 + [bHA]/
KD,bHA)). Each point represents the mean and SD of three independent experiments 
(unless otherwise specified) performed in quadruplicate.  
 
For calculating cooperativity, the effect of multiple substitutions is measured directly 
(observed value). The expected value for a combination of substitutions is calculated as 
the product of the peptide Kd fold changes resulting from single substitutions as 
compared to wtHA [e.g. ΔKd,exp x,y = (ΔKd, x) x (ΔKd,  y)]. The cooperativity is the ratio 
of the expected to observed (C = obs/exp) values for ΔKd. 
HLA-DR1, the human MHCII molecule, is seen complexed with 
the HA peptide. The DR1 α-chain is in green and the β-chain in 
blue. The magenta peptide residues interact with the shallow 
shelves of the DR molecule, orange peptide residues 
conversely interact with the deeper pockets P1, P4, P6, and P9 
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Table I - The sequence of the HA306-319 peptide from H3N2 influenza virus is 
indicated in the second row. The peptide binds through encapsulation of 
hydrophobic side-chains in polymorphic pockets located at the extremities of the 
HLA-DR1 binding groove (P1 and P9). Shallower pockets are lining the groove 
(P2, P4, P6 and P7) and interactions at these positions also contribute to the 
binding. Finally, there is an extensive H-bond network between side chains of 
non-polymorphic residues in the DR1 alpha helixes and the peptide backbone 
(not shown). The substitutions applied via cycle mutation are indicated in the 
third row.  
TM
HLA-DR1 complexed with the HA-derived peptide carrying all the 
applied substitutions as indicated in table 1: P1,2,4,7 VDEG. These 
substitutions are not conservative and result in decrease of peptide 
binding. Graphically modeled residue substitutions of P1,2,4,7 VDEG 
suggest a reduced surface interaction between the peptide and the 
DR1 binding groove, likely resulting in increase of solvation and 
complex destabilization. 
Results 
Peptide affinity was measured using an equilibrium-based competition-binding assay in which each peptide was tested for 
its ability to compete against the HA peptide for binding to DR1. This allowed us to examine cooperativity in highly 
unstable multisubstituted complexes. The binding curves at pH 5.4, 6.4 and 7.4 for all the complexes are shown below 
(Figure A - C). Each individual substitution resulted in small to negligible effects on the dissociation constant whereas 
multiple substitutions had significantly larger effects. This large increase in dissociation constant suggested a cooperative 
effect, and it appeared to be a function of pH (Figure D). To test this possibility, the relative effect of each singly 
substituted complex was calculated with respect to the peptide affinity for the unsubstituted DR1/HA complex. If the 
contribution of each substitution to complex stability was independent, then the effect of multiple substitutions should 
equal the product of their individual effects on stability. The ratio of expected to observed stability gives the cooperativity. 
The data clearly indicate the presence of cooperative effect between the peptide and the MHCII in generating the final 
complex, and protonation impacts the magnitude of the phenomenon. Plotting the cooperativity values and Kd for each 
multisubstituted complex on a ln scale revealed an increasing cooperativity with decreasing Kd, as the data can be fit to a 
linear regression with a positive slope, and the slope values appear to be correlated to pH binding conditions (Figure E). 
pDR1 is shown complexed with a T-Cell 
Receptor (TCR). The α and β chains of the 
TCR are respectively in red and yellow. Blue 
and Green represent the α and β chain of DR1. 
Represented by the color magenta, is the HA 
peptide.  
Peptide pH 5.4 KD 
(nM) 
pH 6.4 KD 
(nM) 
 
pH 7.4 KD 
(nM) 
 
wtHA 2.39 3.02 3.71 
P1V 26.8 12.1 10.4 
P7G 6.42 5.29 6.88 
P17VG 47.8 282 258 
Table II – Reported are affinity values for three peptides 
as exemplification of the effect of pH on binding strength. 
Presently, our results indicate that a trend exists between solvent protonation and 
peptide binding to DR1, though this effect is not consistent, rather dependent on the 
position and nature of the substitution. Because some peptides have been assayed 
only in a single experiment we are not yet able to asses statistical significance of the 
observed differences. However, as cooperativity is a surrogate measurement of 
folding, and a correlation between solvent protonation and protein folding has been 
extensively show in other systems, we expect to observe a confirmation of this initial 
trend. Any result will provide important insights to understand the effect of pH on 
antigen presentation by MHCII molecules and it will impact our ability to predict 
peptide binding and epitope selection. 
Acknowledgements 
 
Dr. Andrea Ferrante and J. Margaret Castellini for excellent mentorship, instruction, 
and resources; Ian Charold Herriott for technical instruction and assistance. 
 
Figure A Figure B Figure C 
Figure D Figure E 
y = 0.6984x + 9.0124 
R² = 0.73683 
y = 0.7801x + 12.114 
R² = 0.97632 
y = 0.671x + 10.219 
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